An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Rocatinlimab (AMG 451) Autoinjector and Vial in Healthy Subjects

The main objective of this study is to evaluate the pharmacokinetics (PK) of rocatinlimab given as a single subcutaneous (SC) autoinjector dose compared to vial in healthy participants.

开始日期2024-08-06

申办/合作机构

Amgen, Inc.

NCT06527404

/ Active, not recruiting临床3期

A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).

开始日期2024-07-18

申办/合作机构

Amgen, Inc.

NCT06376045

/ Active, not recruiting临床2期

A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

开始日期2024-05-24

申办/合作机构

Amgen, Inc.

100 项与诺卡替利单抗相关的临床结果

登录后查看更多信息

100 项与诺卡替利单抗相关的转化医学

登录后查看更多信息

100 项与诺卡替利单抗相关的专利（医药）

登录后查看更多信息

项与诺卡替利单抗相关的文献（医药）

2026-03-23·Cureus Journal of Medical Science

Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents

Review

作者: Babul, Najib ; Soliman, Yssra ; Babul, Arya ; Mehta, Devina ; Hussain, Momina

Biologic therapies targeting maladaptive type 2 inflammation have transformed the management of moderate‑to‑severe atopic dermatitis (AD); however, comparative evidence integrating both approved and next‑generation investigational agents remains limited. This Bayesian network meta‑analysis (BNMA) provides the first unified evaluation of all biologic monoclonal antibodies approved as monotherapy for AD (dupilumab, lebrikizumab, tralokinumab) together with emerging immunotherapies, including amlitelimab, rademikibart, rezpegaldesleukin, rocatinlimab, telazorlimab, temtokibart, and zumilokibart, across key efficacy measures. A PRISMA‑2020-compliant systematic review and PROSPERO‑registered protocol (CRD420251162704) identified phase 2-3 randomized, double‑blind, placebo‑controlled trials reporting week‑16 outcomes (week‑24 for rocatinlimab). A Bayesian random‑effects NMA estimated relative risks (RRs) for EASI‑75, EASI‑90, IGA‑AD 0/1, and ≥4‑point improvement in itch Numeric Rating Scale (NRS). Treatment hierarchy was evaluated using both Bayesian (SUCRA) and frequentist (P‑score) approaches. Seventeen randomized controlled trials (RCTs) involving more than 6,000 patients were included in the analysis. Dupilumab demonstrated the most consistent and reliable efficacy across all evaluated endpoints, including improvements in EASI-75, EASI-90, IGA-AD 0/1, and itch NRS. Among investigational therapies, rocatinlimab showed a notable signal for deep clinical responses, although the available evidence remains limited and less precise. Other emerging agents, including rademikibart, temtokibart, and zumilokibart, demonstrated encouraging efficacy profiles, whereas telazorlimab showed comparatively modest clinical benefit. Ranking analyses consistently positioned dupilumab as the most reliable and highest-performing therapy overall, followed by rocatinlimab. Overall, biologic therapies were generally well tolerated in the short term; however, dupilumab remains the only agent supported by extensive long-term safety data extending up to a decade. This analysis relied on indirect comparisons anchored to short‑term placebo‑controlled induction periods, limiting assessment of long‑term safety and durability, particularly for mechanistically distinct agents such as rezpegaldesleukin, a regulatory T cell (Treg) pathway agonist, and rocatinlimab, an OXO pathway inhibitor. Evidence for several emerging therapies was restricted to small phase 2 trials, resulting in wide credible intervals (Crls) and lower certainty in comparative rankings. Trial heterogeneity in baseline severity, ethnic composition, and geographic setting may have introduced residual confounding despite sensitivity and meta‑regression analyses. These factors should be considered when interpreting relative efficacy estimates This NMA demonstrates that dupilumab remains the most reliable and effective biologic monotherapy for moderate‑to‑severe AD, supported by the greatest precision, reproducibility, and long‑term safety. Rocatinlimab shows promising investigational efficacy but requires efficacy and long-term safety validation. Zumilokibart, rademikibart, and temtokibart emerge as additional candidates with encouraging activity, whereas telazorlimab showed limited clinical benefit. Collectively, these findings provide a comprehensive comparative framework to inform biologic selection and therapeutic sequencing.

2026-03-01·BIODRUGS

The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis

Review

作者: Alvarenga, José Miguel ; Torres, Tiago ; Mohamed, Adam ; Oliveira Dos Santos, David ; Mohamed, Amir

Atopic dermatitis is a chronic inflammatory skin disease affecting approximately 15-20% of children and 2-10% of adults worldwide. Epidermal barrier dysfunction and immune dysregulation are central to its pathogenesis, creating a self-perpetuating cycle in which barrier disruption exacerbates inflammation, which in turn further impairs skin barrier integrity. The OX40/OX40L axis, involving the co-stimulatory receptor OX40 expressed on T cells and its ligand OX40L on antigen-presenting cells, plays a critical role in sustaining T cell-driven inflammatory responses in AD. Despite recent therapeutic advances, many patients remain inadequately controlled, and key unmet needs persist. Inhibitors of the OX40/OX40L pathway represent a novel therapeutic approach by modulating multiple effector and memory T-cell subsets implicated in disease pathogenesis. Amlitelimab, an anti-OX40L monoclonal antibody, has demonstrated sustained efficacy and a favorable safety profile in phase IIa and IIb trials. Rocatinlimab, targeting OX40, has also shown promising results in a phase IIb study and has progressed into multiple phase III trials, with supportive top-line data. In contrast, telazorlimab has shown more modest efficacy and has not advanced to later-stage development. Next-generation agents, including IMG-007, STAR-0310, APG990, and APG279, have been engineered with extended half-lives and attenuated antibody-dependent cellular cytotoxicity to support longer dosing intervals and improve tolerability. While these findings are encouraging, direct comparative studies among agents and versus established therapies are lacking, and long-term efficacy and safety data are still needed. This narrative review explores the role of the OX40/OX40L axis in atopic dermatitis pathogenesis and critically evaluates emerging therapies targeting this pathway, aiming to inform their future integration into clinical practice.

2026-02-01·Dermatology and Therapy

Psychometric Evaluation of Worst Pruritus Numeric Rating Scale in Adults With Moderate-to-Severe Atopic Dermatitis

Article

作者: Blauvelt, Andrew ; Williams, Angela ; McLeod, Lori ; Deininger, Kimberly M ; Qin, Shanshan ; Nelson, Lauren

INTRODUCTION:

Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a hallmark symptom of pruritus. We developed Worst Pruritus Numeric Rating Scale (NRS)-a single-item, patient-reported outcome measure-to assess itch severity in clinical trial populations of adults with moderate-to-severe AD. The objective of this study was to evaluate the psychometric properties of Worst Pruritus NRS and determine its appropriateness for use in clinical trials assessing the efficacy of treatments among adults with moderate-to-severe AD.

METHODS:

We used data from a subset of 267 participants in a phase 2 clinical trial of rocatinlimab (NCT03703102; N = 274) to confirm reliability, validity, and ability to detect change in Worst Pruritus NRS. We estimated and confirmed a meaningful within-patient change (MWPC) threshold using anchor- and distribution-based methods.

RESULTS:

All intraclass correlation coefficients (ICCs) were ≥ 0.86, providing robust evidence for test-retest reliability. Evidence supported construct validity, including known-groups validity (all P < 0.0001). There were moderate, positive correlations between scores on Worst Pruritus NRS and supportive measures at week 16, including Dermatology Life Quality Index (DLQI) question 1 (itch item) (r = 0.78), DLQI (r = 0.66), Eczema Area and Severity Index (EASI) (r = 0.50), Investigator's Global Assessment (IGA) (r = 0.46), Body Surface Area of Involvement (BSA) (r = 0.40), and SCORing Atopic Dermatitis (SCORAD) itch item (r = 0.97). On average, patients with better DLQI question 1 scores, EASI, and IGA classifications achieved better (i.e., lower) scores on Worst Pruritus NRS at week 16 (P < 0.0001). Ability to detect change was supported with moderate-to-strong and positive correlations between Worst Pruritus NRS change scores and changes in supporting measures. MWPC estimates confirmed the commonly applied 4-point threshold value and a range of 3 to 4 points as indicative of meaningful within-patient change.

CONCLUSIONS:

Worst Pruritus NRS is a reliable and valid patient-reported outcome measure to assess itch severity in clinical trial settings among adults with moderate-to-severe AD.

257

项与诺卡替利单抗相关的新闻（医药）

2026-05-03

·网易号

安进重返京瓦基林，湿疹药物尽显晚期良好效果！

安进公司将其成功引进的特应性皮炎（AD）药物罗卡替尼的权利归还给了京瓦基林。在给制药技术的声明中，安进的一位发言人指出，此举是其“持续的投资组合优先级过程”的一部分，该过程将使公司把罗卡替尼项目的责任重新交回给其原始开发者。随着安进放弃对抗OX40单克隆抗体（mAb）的开发权，京瓦将全面负责该药物的后续开发、未来的监管申请以及OX40受体激动剂的商业化工作。这家总部位于东京的制药公司计划在2026年上半年向监管机构提交罗卡替尼的特应性皮炎申请。如果罗卡替尼获得监管批准，京瓦计划“通过灵活的市场逐个进行药物商业化，首先从美国开始”，该公司的总裁兼首席运营官阿卜杜勒·穆利克在接受制药技术采访时表示。穆利克说：“京瓦基林对罗卡替尼单抗在满足中重度AD患者的关键的未满足需求方面的潜力充满信心，这些患者正在寻找能够应对不可预测发作的持久新选择。罗卡替尼单抗的科学原理和其独特的作用机制，针对OX40受体，使其成为一种可能独特的治疗选择。”GlobalData的基于患者的数据预测，预计到2033年，罗卡替尼单抗将在AD领域创造17亿美元的全球销售。OX40配体在AD中的作用曾被认为是AD最有前景的新靶点之一，但由于试验数据未能达到预期，分析师对OX40药物类别的热情受到打击。这是因为最近罗卡替尼单抗和赛诺菲竞争对手OX40候选药物阿米替利单抗的晚期疗效和安全性结果反响平淡。在罗卡替尼单抗的III期试验ROCKET-IGNITE、ROCKET-HORIZON和ASCEND中，该药物达成了所有共同主要和次要终点，但疗效结果普遍未能达到分析师的预期。对于amlitelimab来说，结果也是类似的，它未能延续赛诺菲和再生元畅销AD药物Dupixent（dupilumab）的辉煌，这让GlobalData的分析师推测，该药物将在第二或第三线治疗中得到最多应用。在AD的II期ATLANTIS试验（NCT05769777）中，amlitelimab的治疗还引发了一例与已知风险因素相关的皮肤Kaposi肉瘤病例——这是一种与OX40缺乏相关的罕见血管癌症。在一份研究报告中，威廉·布莱尔分析师Matt Phipps指出，这一发现“可能对OX40类药物带来真正的安全风险”。然而，Mullick认为，OX40配体（amlitelimab）和OX40受体（rocatinlimab）之间的机制差异意味着“一个的发现不应预测另一个的结果”。AD中的未满足需求近年来，生物制剂在AD治疗领域带来了根本性的变化，像Dupixent这样的疗法为患者提供了显著的症状缓解，并且显示出一定的疾病修饰潜力。尽管取得了这些进展，穆利克警告说，许多患者未能达到最佳治疗目标。“超过50%的接受系统治疗的患者在第一年内停止治疗，这突显了仍然需要能够提供更长期控制疾病的治疗选择，”他说。穆利克表示，rocatinlimab的独特作用机制使其“与众不同”，作为治疗选择，它在多种临床场景中的潜力不断扩大。来自GlobalData的最新报告，即制药技术的母公司，预测到2033年，AD市场在七个主要市场（7MM：美国、法国、德国、意大利、西班牙、英国和日本）将达到224亿美元。

2026-05-01

·Neuronlink

湿疹反复发作，真不是“没治彻底”——原来是皮肤里的“记忆细胞”在作祟！

你是否也有这样的困扰：湿疹（特应性皮炎）好不容易好了，没过几周又卷土重来？明明按时抹药、注意保湿，为什么皮肤还是“记性好得让人抓狂”？别急，最新的医学研究给了我们一个令人惊讶的答案：你的皮肤，可能真的“记住了”炎症。🧠皮肤也有“免疫记忆”？是的，而且它太“敬业”了我们身体里的免疫系统有一类特殊的细胞，叫做记忆T细胞和记忆B细胞。它们像是一支训练有素的“特种部队”，一旦曾经遇到过“敌人”（比如过敏原、刺激物），就会长期驻扎在皮肤里，随时准备“再战”。在特应性皮炎患者身上，这些记忆细胞即使在皮肤看起来已经好了的地方，也依然存在。一旦环境变化、屏障受损，它们就会迅速“复活”，释放炎症因子，引发新一轮的瘙痒、红斑、脱屑。 📌 这就是为什么湿疹总是“反反复复”——不是你治得不好，而是这些记忆细胞太“顽固”。 🧬哪些细胞在“捣乱”？文章中指出，以下几种免疫记忆细胞是罪魁祸首：细胞类型特点作用TRM细胞（组织驻留记忆T细胞）长期驻扎在皮肤中一旦激活，迅速引发局部炎症CLA+ T细胞表达皮肤归巢受体，可在血液中检测到反映疾病活动性，是潜在的“外周生物标志物”Th2A细胞一种特殊的Th2记忆细胞同时产生IL-5、IL-13、IL-31，引发剧烈瘙痒MBC2细胞（2型记忆B细胞）表达IL-4受体和CD23 可转化为高亲和力IgE，参与过敏反应这些细胞不仅在活动期存在，在临床缓解期也依然潜伏在皮肤中，维持着一种“亚临床炎症”状态。💊现在的生物制剂能“清除”这些记忆细胞吗？目前临床上常用的抗IL-4/IL-13药物（如dupilumab）确实能显著改善症状，减少血液中的CLA+ T细胞。但研究也发现：即使使用一年，皮肤中的TRM细胞仍然存在。这意味着，一旦停药，复发的风险依然很高。 📌 所以，目前的治疗更多是“控制”，而非“根治”。🎯未来的希望：靶向记忆细胞的“疾病修饰”疗法那有没有办法真正“抹去”这些不好的免疫记忆呢？科学家们正在探索一个全新的治疗方向：疾病修饰。也就是说，通过靶向那些维持记忆细胞生存的关键通路，让皮肤“忘记”炎症。其中一个非常有前景的靶点是OX40/OX40L通路。这个通路像是记忆细胞的“充电桩”，阻断它，就能：减少Th2、Th17、Th22等病理T细胞的生成抑制TRM细胞的形成和驻留实现停药后仍能维持缓解目前，多个靶向OX40/OX40L的药物（如rocatinlimab、amitelimab）已在临床试验中显示出持久疗效，部分患者在停药后仍能保持无复发状态长达20周。 🌱“超级应答者”：谁最有可能实现长期缓解？研究中还提到了一类特殊人群——超级应答者。他们通常在治疗开始后16–24周内就达到显著改善，并且这种效果能维持到一年以上。识别这些患者，不仅有助于个性化治疗，也为“疾病修饰”提供了宝贵的线索：哪些免疫通路在这些人身上更容易被“重新编程”？🧭总结：我们离“治愈”湿疹还有多远？虽然目前还没有任何药物被官方认定为“疾病修饰”药物，但我们已经走在正确的路上： ✅ 我们知道了哪些细胞在“记忆”炎症 ✅ 我们找到了维持这些记忆的关键通路 ✅ 我们正在开发能真正清除这些记忆的药物 📌 未来的治疗目标，不再是“压住症状”，而是让皮肤忘记炎症。💬写给每一位湿疹患者你不是“太敏感”，也不是“没治好”。你只是皮肤里的免疫记忆太强了。好在，科学正在一步步破解这个难题。也许在不远的将来，湿疹真的可以“一劳永逸”。如果你觉得这篇文章有帮助，欢迎点赞、在看、转发给更多朋友，让更多人了解湿疹背后的“免疫记忆”秘密！参考文献 Domínguez-López R, Berna-Rico E, Gomez-de la Fuente E, Pérez-García B, Aranda CJ, Abbad-Jaime de Aragón C, et al. Immunological memory in atopic dermatitis: towards disease modification. Int J Mol Sci. 2026;27(23):2371. 阿尔茨海默病与胶质母细胞瘤：同一信号网络手术伤口中的“意外信使”：IL-7如何影响中性粒细胞，加剧术后疼痛？ Cell重磅综述：不只是凋亡，揭秘癌症与“细胞死亡”的全局战争化疗后手脚麻木、疼痛？新研究教你提前预测风险！

2026-04-30

·拓麦Derm

AAD 2026视频特辑｜Raj Chovatiya教授：2026 AAD 皮肤病治疗进展全景回顾

点击蓝字关注“拓麦Derm” Prof. Raj Chovatiya ◆ Rosalind Franklin University of Medicine and Science 肖像经Prof. Raj Chovatiya许可后使用本期特邀美国罗莎琳德・富兰克林医科大学芝加哥医学院、芝加哥医学皮肤病学与免疫学研究中心创始人兼主任Raj Chovatiya教授分享在2026年AAD大会上炎症性皮肤病领域的最新进展。 ▼ 点击小程序，观看完整内容 ▼ 在2026年丹佛举行的美国皮肤病学会年会上，来自罗莎琳德·富兰克林大学的Raj Chovatiya教授带来了多场精彩报告，内容覆盖白癜风、特应性皮炎、银屑病、化脓性汗腺炎等多个炎症性皮肤病领域的最新进展。白癜风：从沉重负担到新兴希望 Raj Chovatiya教授结合自身南亚裔背景，深入剖析了白癜风在全球不同人群中的独特疾病负担。他指出，白癜风对深肤色患者的心理和社会影响尤为严重。在治疗方面，外用芦可替尼（ruxolitinib）已成为里程碑式的突破。关键III期TRuE-V研究显示，治疗24周时，约30%的患者达到面部白癜风面积评分指数较基线改善≥75%（F-VASI75），52周时这一比例进一步提高至约50%，且安全性良好。此外，口服JAK抑制剂也展现出广阔前景：乌帕替尼（upadacitinib）在II期研究中显著促进皮损复色，利特昔替尼（ritlecitinib）和Povorcitinib同样在临床试验中取得了积极结果，为不适合或不愿外用治疗的患者提供了新的选择。关注肤色差异，推动个体化治疗在特应性皮炎、银屑病和化脓性汗腺炎的报告中，Raj Chovatiya教授强调不同种族、肤色人群在疾病表现和治疗反应上存在显著差异。例如，银屑病在深色皮肤患者中常表现为紫灰色斑块，而红斑表现不典型，易被延误诊断。他重点介绍了专门针对深肤色患者设计的大规模临床试验： • 利生奇珠单抗（risankizumab）用于银屑病：在深肤色患者中，16周PASI 90应答率超过80%，疗效与浅肤色人群一致，且安全谱无差异。 • 度普利尤单抗（dupilumab）用于特应性皮炎：在深肤色患者中同样达到EASI-75（湿疹面积及严重度指数改善75%）应答率约65%-70%，瘙痒NRS评分下降显著。 • Lebrikizumab 用于特应性皮炎：在深肤色亚组中，16周EASI-75应答率达65%-70%，持续治疗至52周仍保持稳定控制。这些数据验证了现有评估工具在深肤色患者中的适用性，为全球多样化人群提供了更公平的治疗依据。基础科学新视角：表皮屏障与2型炎症 Raj Chovatiya教授重新解读了表皮屏障的基础科学，以特应性皮炎为例，阐释了2型炎症（IL-4、IL-13等）如何抑制角质形成细胞分化、减少天然保湿因子和神经酰胺合成，导致屏障功能受损、经皮水分丢失增加。他强调，理解这一机制有助于靶向治疗更精准地修复屏障，而非仅仅控制炎症。 JAK抑制剂与生物制剂持续更新 Raj Chovatiya教授分享了多项临床研究的最新结果： • 阿布昔替尼（abrocitinib）：在JADE系列III期研究中，200mg剂量组12周时EASI-75应答率达60%-70%，瘙痒NRS评分改善≥4分的患者比例约50%-60%。长期扩展研究显示，疗效维持至96周，安全性特征与既往一致。 • 乌帕替尼（upadacitinib）：在Measure Up系列研究中，30mg剂量组16周EASI-90应答率超过60%，在重度AD患者中表现尤为突出。 • Nemolizumab（抗IL-31受体抗体）：在特应性皮炎和结节性痒疹中均显示快速缓解瘙痒，16周时瘙痒NRS改善≥4分的患者比例达40%-50%。 Lebrikizumab、度普利尤单抗、曲罗芦单抗（tralokinumab）的长期数据进一步巩固了IL-13/IL-4通路在AD治疗中的核心地位。未来新靶点：OX40/OX40L通路与IL-2受体激动剂 Raj Chovatiya教授重点介绍了两个极具潜力的新兴机制： • OX40/OX40L通路：该通路调控T细胞活化和记忆T细胞形成。靶向此通路有望实现“疾病修饰”，即停药后仍维持长期缓解。相关抗体（如rocatinlimab、amlitelimab）在II期研究中显示出持续数月的停药后控制，III期研究正在进行中。 • Rezpegaldesleukin（Rezpeg）：一种IL-2受体激动剂，通过选择性调节调节性T细胞（Treg）来重建免疫稳态。在II期研究中，治疗组患者的EASI评分较基线改善超过50%的患者比例显著高于安慰剂组，且耐受性良好，未出现严重不良事件。 Raj Chovatiya教授总结道，2026年AAD年会是一次极具成果的学术盛会。从白癜风的靶向治疗、深肤色患者的包容性数据，到JAK抑制剂和生物制剂的长期验证，再到OX40/OX40L和IL-2受体激动剂等全新机制，皮肤病治疗正朝着更精准、更持久、更公平的方向飞速发展。他鼓励全球皮肤科同道继续加强合作，共同推动科研与临床实践的创新。关于AAD 2026视频特辑（Special Edition）为了给广大医学同仁带来更丰富、更深入的学术资讯，拓麦编辑部精心策划并推出了AAD 2026视频特辑，并特别邀请到国际银屑病理事会（IPC）首席医学官、荷兰拉德堡德大学奈梅亨医学中心Peter van de Kerkhof教授担任主编，从专业视角出发，共同为大家呈现了此次兼具学术性与前沿性的视频特辑。更多详情请点击查看AAD 2026视频特辑专区！ ▼ 点击查看AAD 2026视频特辑专区 ▼ 点击关注 “拓麦DERM”，即刻获取国际皮肤病学领域前沿洞见 1 END 1 供稿：Jason 审核：Jaya 排版：Vanessa / Haojun 版权声明: 内容仅限医疗卫生专业人士学习交流使用，非医疗卫生专业人士请主动退出浏览与阅读，否则由此产生的相关风险与后果应自行承担。未经版权所有者事先许可，不得以任何方式或任何手段对内容涉及的任何文档、图片、音频、视频复制、储存在其他第三方平台；未经版权所有者许可不得以任何方式（包括但不限于：嵌套、深度链接、盗播、盗取、盗链等）直接或间接地使用相关视频内容从事任何商业活动，否则将保留追究侵权者相关法律责任的权利。肖像经Prof. Raj Chovatiya许可后使用。参考来源： 1. Raj J. Chovatiya. Keratinocyte Biology, Barrier Function, and the Microbiome: A Template for Type 2 Inflammatory Skin Disease. Session ID: F022. AAD 2026, 27-31 Mar, Denver USA 2. Raj J. Chovatiya. Raj Chovatiya - Vitiligo: From Historical Perspectives to Targeted Therapies. Session ID: F035. AAD 2026, 27-31 Mar, Denver USA 3. Raj J. Chovatiya. Inflammatory Disorders Part 2. Session ID: S045. AAD 2026, 27-31 Mar, Denver USA 4. Raj J. Chovatiya, et al. Using Statistical Modeling to Predict Abrocitinib Response After Early Dose Escalation. Poster ID: 75832. AAD 2026, 27-31 Mar, Denver USA 5. Raj J. Chovatiya, et al. Tailoring Treatment With Abrocitinib: Personalized Treatment Approaches Used in the JADE REAL Study. Poster ID: 75816. AAD 2026, 27-31 Mar, Denver USA #AAD 2026

100 项与诺卡替利单抗相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结节性痒疹	临床3期	美国	Amgen, Inc.	2024-07-08
中度特应性皮炎	临床3期	美国	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	中国	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	日本	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	阿根廷	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	巴西	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	加拿大	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	克罗地亚	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	捷克	Amgen, Inc.	2022-05-31
中度特应性皮炎	临床3期	德国	Amgen, Inc.	2022-05-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05899816 (ROCKET-VOYAGER, AAAAI2026)	临床3期	中度特应性皮炎	221	Rocatinlimab	觸鏇齋糧觸遞鏇鏇鑰鹽(鹽範醖簾築獵繭積淵簾) = 獵膚夢鑰網範衊餘廠醖齋鹹膚簾願壓壓觸獵繭 (壓壓壓鬱鏇鹽範願醖蓋 ) 更多	积极	2026-02-27
				Placebo	觸鏇齋糧觸遞鏇鏇鑰鹽(鹽範醖簾築獵繭積淵簾) = 鹽獵鑰顧鑰壓夢鹹選廠齋鹹膚簾願壓壓觸獵繭 (壓壓壓鬱鏇鹽範願醖蓋 ) 更多
NCT05398445 (ROCKET-IGNITE, Company_Website) 人工标引	临床3期	特应性皮炎	769	Rocatinlimab higher dose	願襯選餘簾艱憲窪網夢(鹹積餘遞觸範獵廠範鹽) = 製觸範艱願網範齋願遞夢艱淵淵襯繭淵艱艱壓 (遞襯餘鏇鏇鏇夢憲憲觸 ) 达到更多	积极	2025-03-08
				Rocatinlimab lower dose	願襯選餘簾艱憲窪網夢(鹹積餘遞觸範獵廠範鹽) = 簾鏇膚膚顧選範鹹繭構夢艱淵淵襯繭淵艱艱壓 (遞襯餘鏇鏇鏇夢憲憲觸 ) 达到更多
NCT05724199 (ROCKET-SHUTTLE, Company_Website) 人工标引	临床3期	重度特应性皮炎	746	Rocatinlimab higher dose + TCS/TCI	鑰夢醖憲齋憲繭網膚構(觸憲憲壓糧鹹築蓋觸膚) = 繭壓遞網襯鹹齋範遞鏇遞窪選艱願獵鑰廠構鑰 (醖獵鬱顧淵壓醖艱淵襯 ) 达到更多	积极	2025-03-08
				Rocatinlimab lower dose + TCS/TCI	鑰夢醖憲齋憲繭網膚構(觸憲憲壓糧鹹築蓋觸膚) = 膚構艱鑰醖夢鏇窪構淵遞窪選艱願獵鑰廠構鑰 (醖獵鬱顧淵壓醖艱淵襯 ) 达到更多
NCT05651711 (ROCKET HORIZON, Corporate Publications) 人工标引	临床3期	特应性皮炎	726	Rocatinlimab	鹹築觸獵製廠餘構窪廠(網夢範淵衊齋繭選糧顧) = 壓簾鹹憲艱積蓋淵鏇構淵簾遞蓋窪鏇憲齋夢積 (築廠簾積鏇願夢鏇糧獵 ) 达到更多	积极	2024-09-25
				Placebo	鹹築觸獵製廠餘構窪廠(網夢範淵衊齋繭選糧顧) = 範齋鹹鹹襯醖構蓋築齋淵簾遞蓋窪鏇憲齋夢積 (築廠簾積鏇願夢鏇糧獵 ) 达到更多
NCT05651711 (ROCKET HORIZON, Company_Website) 人工标引	临床3期	重度特应性皮炎	726	Rocatinlimab	淵淵鹽顧艱鑰鬱構顧餘(艱襯醖襯遞簾淵鹹壓簾) = 獵艱選鹽製淵鹽齋窪鏇鹽觸積簾願衊淵齋鏇衊 (顧糧夢夢製選築範憲餘 ) 达到更多	积极	2024-09-25
				Placebo	淵淵鹽顧艱鑰鬱構顧餘(艱襯醖襯遞簾淵鹹壓簾) = 膚糧遞獵壓鑰鏇窪築獵鹽觸積簾願衊淵齋鏇衊 (顧糧夢夢製選築範憲餘 ) 达到更多
NCT03703102 (CTgov)	临床2期	中度特应性皮炎 \| 重度特应性皮炎	274	KHK4083 (KHK4083 150 mg SC Q4W)	廠築壓鑰憲夢鬱網鏇淵(鹽餘觸憲鬱鏇餘衊鑰窪) = 齋簾襯膚膚選簾糧築築壓鬱鑰醖淵醖願網膚顧 (襯範淵鬱願艱築積糧膚, 糧醖夢糧鬱觸壓網淵顧 ~ 網願觸餘鹽觸鹹網製遞) 更多	-	2022-06-09
				KHK4083 (KHK4083 600 mg SC Q4W)	廠築壓鑰憲夢鬱網鏇淵(鹽餘觸憲鬱鏇餘衊鑰窪) = 襯夢膚鹹夢膚鹽選遞築壓鬱鑰醖淵醖願網膚顧 (襯範淵鬱願艱築積糧膚, 夢窪製憲觸構遞廠鏇糧 ~ 衊襯憲鬱鬱鬱遞選窪製) 更多
NCT02647866 (CTgov)	临床2期	腹痛 \| 溃疡性结肠炎	66	KHK4083 (KHK4083 Cohort 1)	構窪鑰鹹構範憲廠製鬱 = 糧顧製艱艱襯糧憲鹽鏇鑰餘積觸製餘蓋繭窪選 (膚鏇網築遞鏇餘糧艱網, 遞顧願夢觸淵構網簾鏇 ~ 製壓遞壓憲淵糧願選繭) 更多	-	2020-03-05
				KHK4083 (KHK4083 Cohort 2)	構窪鑰鹹構範憲廠製鬱 = 構積憲遞淵憲範廠醖獵鑰餘積觸製餘蓋繭窪選 (膚鏇網築遞鏇餘糧艱網, 鏇蓋獵遞獵願膚蓋遞繭 ~ 鹹壓蓋廠襯構廠鹹製壓) 更多